Novavax may have a 'game changer' COVID-19 vaccine on its hands

Author: Eamonn Sheridan | Category: News

The Wall Street Journal with the report 

The Novavax vaccine, it says, offers key possible advantages over its competitors:
  • early data suggest the Novavax shot may be one of the first shown to stem asymptomatic spread of the coronavirus
  • and also potentially provide longer-lasting protection
Its a 2 shot vaccine. Approval still appears a couple of months away.

Here is the link for more, its the WSJ so may be gated.
An interesting read but the firm has clearly lost first-mover advantage and by the time it gets approval, then into distribution, it might well be too late? 

The Wall Street Journal with the report 
By continuing to browse our site you agree to our use of cookies, revised Privacy Notice and Terms of Service. More information about cookiesClose